Interferon-&ggr; 1b: impact of new indications (idiopathic pulmonary fibrosis)

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.1, Iss.7, 2000-12, pp. : 1423-1427

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis

By Ding Qiang Luckhardt Tracy Hecker Louise Zhou Yong Liu Gang Antony Veena B. deAndrade Joao Thannickal Victor J.

Drugs, Vol. 71, Iss. 8, 2011-05 ,pp. : 981-1001

Adis International

Access to resources Recommend Favorite

Pirfenidone: In Idiopathic Pulmonary Fibrosis

By Carter Natalie J.

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1721-1732

Adis International

Access to resources Recommend Favorite

Recognition and Treatment of Idiopathic Pulmonary Fibrosis

By Nicod L.P.

Drugs, Vol. 55, Iss. 4, 1998-04 ,pp. : 555-562

Adis International

Access to resources Recommend Favorite

Emerging drugs for idiopathic pulmonary fibrosis

By Selman Moiséés Pardo Annie Richeldi Luca Cerri Stefania

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 2, 2011-06 ,pp. : 341-362

Informa Healthcare

Access to resources Recommend Favorite

Pharmacotherapy in patients with idiopathic pulmonary fibrosis

By Nagai S Handa T Kim DS

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 11, 2008-08 ,pp. : 1909-1925

Informa Healthcare

Access to resources Recommend Favorite